Health Canada
Symbol of the Government of Canada
Skip to content | Skip to institutional links

Common menu bar links

Home > First Nations & Inuit Health > Reports & Publications > Non-Insured Health Benefits

Institutional links

First Nations & Inuit Health

Updates to the Drug Benefit List - Spring-Summer 2011

Warning This content was archived on June 24, 2013.

Archived Content

Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

Portable Document Format(PDF Version - 270 K)

The Non-Insured Health Benefits (NIHB) Program provides supplementary health benefits, including prescription and non-prescription drugs, for registered First Nations and recognized Inuit throughout Canada. Visit our Web Site.

Benefit Definitions

Open benefits:
Open benefits are the drugs listed in the NIHB Drug Benefit List (DBL) which do not have established criteria or prior approval requirements.
Limited use benefits:
Limited use drugs are those that have been found to be effective in specific circumstances, or which have quantity and frequency limitations. For drugs in this category, specific criteria must be met to be eligible for coverage.
Not added to the formulary:
Drugs not added to formulary are those which are not listed in the NIHB DBL after review by the national Common Drug Review (CDR) process and/or the Federal Pharmacy and Therapeutics Committee (FP&T). These drugs will not be added to the NIHB drug list because published evidence does not support the clinical value or cost of the drug relative to existing therapies. Coverage may be considered in special circumstances upon receipt of a completed "Exception Drugs Request Form" from the attending licensed practitioner. These requests are reviewed on a case by case basis.
Exclusion:
Certain drug therapies for particular conditions fall outside the NIHB Program's mandate and will not be provided as benefits (e.g., cosmetic and anti-obesity drugs). As well, certain drugs will be excluded from the NIHB Program as recommended by the CDR and the FP&T because published evidence does not support the clinical value, safety or cost of the drukg relative to existing therapies, or there is insufficient clinical evidence to support coverage.

Note: The appeal process and the emergency supply policy does not apply to excluded drugs.

Additions to the Drug Benefit List

Open Benefits

Single-Source Drug Products
DIN MFR Item Name Effective Date
02270811 BAY FINACEA 15% TOPICAL GEL 16-05-2011
02352656 PFI FRAGMIN 10000U/0.4ML SYRINGE 21-04-2011
02352648 PFI FRAGMIN 7500U/0.3ML SYRINGE 21-04-2011
02240342 PDL DIVALPROEX 250MG EC TABLET 15-03-2011
02356422 SEV ST DIAMICRON MR 60MG TABLET 07-03-2011
97799500 LIL HUMULIN N KWIKPEN 08-02-2011
Multi-Source Drug Products
DIN MFR Item Name Effective Date
02237390 PER ACETAMINOPHEN 80MG/ML SUSPENSION 31-01-2011
02352427 ODN ST ASATAB EC 325MG TABLET 02-05-2011
02352435 ODN ST ASATAB EC 650MG TABLET 02-05-2011
02331292 SAN ST AMLODIPINE 10MG TABLET 28-03-2011
02331284 SAN ST AMLODIPINE 5MG TABLET 28-03-2011
02351757 PDL ST ATORVASTATIN 10MG TABLET 15-03-2011
02351765 PDL ST ATORVASTATIN 20MG TABLET 15-03-2011
02351773 PDL ST ATORVASTATIN 40MG TABLET 15-03-2011
02351781 PDL ST ATORVASTATIN 80MG TABLET 15-03-2011
02343002 SAN AZATHIOPRINE 50MG TABLET 14-04-2011
97799532 HOD TRUETEST TEST STRIP (100) 09-05-2011
97799531 HOD TRUETEST TEST STRIP (50) 09-05-2011
80001408 NUR OYSTER SHELL CALCIUM 500MG CAPSULE 02-05-2011
02365367 APX ST APO-CANDESARTAN 16MG TABLET 27-05-2011
02365340 APX ST APO-CANDESARTAN 4MG TABLET 27-05-2011
02365359 APX ST APO-CANDESARTAN 8MG TABLET 27-05-2011
02326973 SDZ ST SANDOZ-CANDESARTAN 16MG TABLET 27-05-2011
02326957 SDZ ST SANDOZ-CANDESARTAN 4MG TABLET 27-05-2011
02326965 SDZ ST SANDOZ-CANDESARTAN 8MG TABLET 27-05-2011
02355248 ACP ACCEL-CITALOPRAM 10MG TABLET 22-03-2011
02355256 ACP ACCEL-CITALOPRAM 20MG TABLET 22-03-2011
02355264 ACP ACCEL-CITALOPRAM 40MG TABLET 22-03-2011
02324482 PDL PRO-CLARITHROMYCIN 250MG TABLET 15-03-2011
02324490 PDL PRO-CLARITHROMYCIN 500MG TABLET 15-03-2011
02309548 PMS PMS-CLOBETASOL 0.05% OINTMENT 15-04-2011
02237736 SWS ST VITAMIN B12 1000MCG TABLET 14-04-2011
02316307 SWS SANDOZ DORZOLAMIDE 20MG/ML 25-03-2011
02299615 APX APO-DORZO-TIMOP 20/5MG SOLUTION 03-02-2011
02326663 STG ERYTHROMYCIN 0.50% OINTMENT 06-05-2011
02356570 SAN ST FENOFIBRATE-S 100MG TABLET 18-03-2011
02356589 SAN ST FENOFIBRATE-S 160MG TABLET 18-03-2011
02286068 SAN FLUOXETINE 10MG CAPSULE 28-03-2011
02286076 SAN FLUOXETINE 20MG CAPSULE 28-03-2011
02317079 PMS ST PMS-IRBESARTAN 150MG TABLET 12-04-2011
02317087 PMS ST PMS-IRBESARTAN 300MG TABLET 12-04-2011
02317060 PMS ST PMS-IRBESARTAN 75MG TABLET 12-04-2011
02316404 RTP ST RATIO-IRBESARTAN 150MG TABLET 12-04-2011
02316412 RTP ST RATIO-IRBESARTAN 300MG TABLET 12-04-2011
02316390 RTP ST RATIO-IRBESARTAN 75MG TABLET 12-04-2011
02328488 SDZ ST SANDOZ IRBESARTAN 150MG TABLET 12-04-2011
02328496 SDZ ST SANDOZ IRBESARTAN 300MG TABLET 12-04-2011
02328461 SDZ ST SANDOZ IRBESARTAN 75MG TABLET 12-04-2011
02315998 TEP ST TEVA-IRBESARTAN 150MG TABLET 12-04-2011
02316005 TEP ST TEVA-IRBESARTAN 300MG TABLET 12-04-2011
02315971 TEP ST TEVA-IRBESARTAN 75MG TABLET 12-04-2011
02328518 PMS ST PMS-IRBESARTAN/HCT 150/12.5MG TABLET 12-04-2011
02328526 PMS ST PMS-IRBESARTAN/HCT 300/12.5MG TABLET 12-04-2011
02328534 PMS ST PMS-IRBESARTAN/HCT 300/25MG TABLET 12-04-2011
02330512 RTP ST RATIO-IRBESART/HCT 150/12.5MG TABLET 12-04-2011
02330520 RTP ST RATIO-IRBESART/HCT 300/12.5MG TABLET 12-04-2011
02330539 RTP ST RATIO-IRBESART/HCT 300/25MG TABLET 12-04-2011
02337428 SDZ ST SANDOZ IRBESART/HCT 150/12.5MG TABLET 12-04-2011
02337436 SDZ ST SANDOZ IRBESART/HCT 300/12.5MG TABLET 12-04-2011
02337444 SDZ ST SANDOZ IRBESART/HCT 300/25MG TABLET 12-04-2011
02316013 TEP ST TEVA-IRBESARTAN/HCT 150/12.5MG TABLET 12-04-2011
02316021 TEP ST TEVA-IRBESARTAN/HCT 300/12.5MG TABLET 12-04-2011
02316048 TEP ST TEVA-IRBESARTAN/HCT 300/25MG TABLET 11-04-2011
02357682 SAN ST LANSOPRAZOLE 15MG CAPSULE 29-03-2011
02357690 SAN ST LANSOPRAZOLE 30MG CAPSULE 29-03-2011
02358514 APX APO-LETROZOLE 2.5MG TABLET 05-03-2011
02351463 SAN ST 5-ASA 400MG TABLET 25-03-2011
02326248 PDL METHYLPHENIDATE 10MG TABLET 18-03-2011
02326256 PDL METHYLPHENIDATE 20MG TABLET 18-03-2011
02326221 PDL METHYLPHENIDATE 5MG TABLET 18-03-2011
02351412 PDL METOPROLOL SR 200MG TABLET 15-03-2011
02350920 SAN MORPHINE SR 100MG TABLET 18-03-2011
02350815 SAN MORPHINE SR 15MG TABLET 18-03-2011
02350947 SAN MORPHINE SR 200MG TABLET 18-03-2011
02350890 SAN MORPHINE SR 30MG TABLET 18-03-2011
02350912 SAN MORPHINE SR 60MG TABLET 18-03-2011
97799566 DPI INSUPEN 29GX12MM NEEDLE 08-02-2011
97799567 DPI INSUPEN 30GX8MM NEEDLE 08-02-2011
97799569 DPI INSUPEN 31GX6MM NEEDLE 08-02-2011
97799568 DPI INSUPEN 31GX8MM NEEDLE 08-02-2011
97799571 DPI INSUPEN 32GX6MM NEEDLE 08-02-2011
97799570 DPI INSUPEN 32GX8MM NEEDLE 08-02-2011
02352893 TEP TEVA-NEVIRAPINE 200MG TABLET 22-03-2011
02360632 APX APO-OLANZAPINE ODT 15MG 29-03-2011
02360616 APX APO-OLANZAPINE ODT 5MG 29-03-2011
02358034 MDS PEG 3350 POWDER 11-04-2011
02356546 SAN ST PRAVASTATIN 10MG TABLET 18-03-2011
02356554 SAN ST PRAVASTATIN 20MG TABLET 18-03-2011
02356562 SAN ST PRAVASTATIN 40MG TABLET 18-03-2011
02361892 PMS PMS-QUETIAPINE 50MG TABLET 07-03-2011
02342138 PMS ST PMS-RAMIPRIL-HCTZ 2.5/12.5MG TABLET 22-03-2011
02342146 PMS ST PMS-RAMIPRIL-HCTZ 5/12.5MG TABLET 22-03-2011
02342162 PMS ST PMS-RAMIPRIL-HCTZ 5MG/25MG TABLET 07-03-2011
02353024 SAN ST RANITIDINE 300MG TABLET 31-03-2011
02321475 CBT ST CO-REPAGLINIDE 0.5MG TABLET 03-02-2011
02321483 CBT ST CO-REPAGLINIDE 1MG TABLET 03-02-2011
02321491 CBT ST CO-REPAGLINIDE 2MG TABLET 03-02-2011
02354926 PMS ST PMS-REPAGLINIDE 0.5MG TABLET 29-03-2011
02354934 PMS ST PMS-REPAGLINIDE 1MG TABLET 29-03-2011
02354942 PMS ST PMS-REPAGLINIDE 2MG TABLET 29-03-2011
02359790 MIN MINT-RISPERIDONE 0.25MG TABLET 22-03-2011
02359804 MIN MINT-RISPERIDONE 0.5MG TABLET 22-03-2011
02359812 MIN MINT-RISPERIDONE 1MG TABLET 22-03-2011
02359820 MIN MINT-RISPERIDONE 2MG TABLET 22-03-2011
02359839 MIN MINT-RISPERIDONE 3MG TABLET 22-03-2011
02359847 MIN MINT-RISPERIDONE 4MG TABLET 22-03-2011
02356880 SAN RISPERIDONE 0.25MG TABLET 22-03-2011
02356899 SAN RISPERIDONE 0.5MG TABLET 28-03-2011
02356902 SAN RISPERIDONE 1MG TABLET 28-03-2011
02356910 SAN RISPERIDONE 2MG TABLET 28-03-2011
02356929 SAN RISPERIDONE 3MG TABLET 28-03-2011
02356937 SAN RISPERIDONE 4MG TABLET 28-03-2011
02340208 SDZ ST SANDOZ TAMSULOSIN 0.4MG CREAM 17-02-2011
02351315 ACP ACCEL-TOPIRAMATE 100MG TABLET 22-03-2011
02351323 ACP ACCEL-TOPIRAMATE 200MG TABLET 22-03-2011
02351307 ACP ACCEL-TOPIRAMATE 25MG TABLET 22-03-2011
02356864 SAN TOPIRAMATE 100MG TABLET 28-03-2011
02356872 SAN TOPIRAMATE 200MG TABLET 28-03-2011
02356856 SAN TOPIRAMATE 25MG TABLET 28-03-2011
02363119 RBY ST RAN-VALSARTAN 160MG TABLET 07-03-2011
02363062 RBY ST RAN-VALSARTAN 40MG TABLET 07-03-2011
02363100 RBY ST RAN-VALSARTAN 80MG TABLET 07-03-2011
02356767 SDZ ST SANDOZ VALSARTAN 160MG TABLET 16-03-2011
02356775 SDZ ST SANDOZ VALSARTAN 320MG TABLET 16-03-2011
02356740 SDZ ST SANDOZ VALSARTAN 40MG TABLET 16-03-2011
02356759 SDZ ST SANDOZ VALSARTAN 80MG TABLET 16-03-2011
02356678 TEP ST TEVA-VALSARTAN 160MG TABLET 07-03-2011
02356686 TEP ST TEVA-VALSARTAN 320MG TABLET 07-03-2011
02356643 TEP ST TEVA-VALSARTAN 40MG TABLET 07-03-2011
02356651 TEP ST TEVA-VALSARTAN 80MG TABLET 07-03-2011
02357003 TEP ST TEVA-VALSARTAN/HCTZ 160/12.5MG TABLET 07-03-2011
02357011 TEP ST TEVA-VALSARTAN/HCTZ 160/25MG TABLET 07-03-2011
02357038 TEP ST TEVA-VALSARTAN/HCTZ 320/12.5MG TABLET 07-03-2011
02357046 TEP ST TEVA-VALSARTAN/HCTZ 320/25MG TABLET 07-03-2011
02356996 TEP ST TEVA-VALSARTAN/HCTZ 80/12.5MG TABLET 07-03-2011
02356708 SDZ ST SANDOZ VALSARTAN HCT 160/12.5 TABLET 16-03-2011
02356716 SDZ ST SANDOZ VALSARTAN HCT 160/25MG TABLET 16-03-2011
02356724 SDZ ST SANDOZ VALSARTAN HCT 320/12.5 TABLET 16-03-2011
02356732 SDZ ST SANDOZ VALSARTAN HCT 320/25MG TABLET 16-03-2011
02356694 SDZ ST SANDOZ VALSARTAN HCT 80/12.5MG TABLET 16-03-2011

New Limited Use Benefits

DIN MFR Item Name Effective Date
02350092 HLR ACTEMRA 80MG/4ML IV SOLUTION 06-04-2011
02350106 HLR ACTEMRA 200MG/10ML IV SOLUTION 06-04-2011
02350114 HLR ACTEMRA 400MG/20ML IV SOLUTION 06-04-2011

Limited use benefit (prior approval required).

For the treatment of adult patients with moderate to severely active rheumatoid arthritis who have failed to respond to an adequate trial of an anti-TNF agent AND

  1. Prescribed by a rheumatologist AND
  2. Patient has had a tuberculin skin test performed.

Note: Treatment should be combined with methotrexate or other DMARD. Tocilizumab should not be used in combination with anti-TNF agents.

DIN MFR Item Name Effective Date
02350270 PDL ST FINASTERIDE 5MG TABLET 22-03-2011
02354462 CBT ST CO-FINASTERIDE 5MG TABLET 11-03-2011

Limited use benefit (prior approval required).

  1. For treatment of Benign Prostatic Hyperplasia (BPH) in patients who do not tolerate or have not responded to an alpha adrenergic blocker; OR
  2. For use in combination therapy when monotherapy with an alpha-blocker is not sufficient.
DIN MFR Item Name Effective Date
02356511 SAN ST RABEPRAZOLE 10MG TABLET 28-03-2011
02356538 SAN ST RABEPRAZOLE 20MG TABLET 28-03-2011

Limited use benefit (prior approval not required).

Coverage will be limited to 400 tablets/capsules every 180 days.

DIN MFR Item Name Effective Date
02347474 PDL ST RISEDRONATE 35MG TABLET 15-04-2011

Limited use benefit (prior approval required).

  • Osteoporosis in patients who are 60 years of age or over OR
  • Paget's Disease OR
  • Osteoporosis in patients under 60 who have documented hip, vertebral or other fractures OR
  • Osteoporosis in patients under 60 with no evidence of fracture but who have a high (>20%) 10-year fracture risk OR
  • Osteoporosis in patients under 60with moderate 10-year fracture risk AND use of systemic glucocorticoid therapy > 3 months
DIN MFR Item Name Effective Date
02246804 JNO LEVAQUIN 750MG TABLET 17-05-2011
02285649 NOP NOVO-LEVOFLOXACIN 750MG TABLET 17-05-2011
02298651 SDZ SANDOZ-LEVOFLOXACIN 750MG TABLET 17-05-2011
02305585 PMS PMS-LEVOFLOXACIN 750MG TABLET 17-05-2011
02315440 CBT CO-LEVOFLOXACIN 750MG TABLET 17-05-2011
02325942 APX APO-LEVOFLOXACIN 750MG TABLET 17-05-2011

Limited use benefit (prior approval not required).

Coverage will be limited to a maximum of 14 days.

DIN MFR Item Name Effective Date
02316943 JNO PAT-GALANTAMINE ER 8MG CAPSULE 24-02-2011
02316951 JNO PAT-GALANTAMINE ER 16MG CAPSULE 24-02-2011
02316978 JNO PAT-GALANTAMINE ER 24MG CAPSULE 24-02-2011
02339439 MYL MYLAN-GALANTAMINE ER 8MG TABLET 24-02-2011
02339447 MYL MYLAN-GALANTAMINE ER 16MG TABLET 24-02-2011
02339455 MYL MYLAN-GALANTAMINE ER 24MG TABLET 24-02-2011

Limited use benefit (prior approval required).

Initial six month coverage for cholinesterase inhibitors:

  • Diagnosis of mild to moderate Alzheimer's disease; AND
  • Mini Mental State Exam (MMSE) score of 10-26, established within the last 60 days; AND
  • Global Deterioration Scale (GDS) score between 4 to 6, established within the last 60 days
  • Continued coverage beyond 6 months will be based on improvement or stabilization of cognition, function or behaviour.

Criteria for coverage at every six month interval:

  • Diagnosis is still mild to moderate Alzheimer's disease; AND
  • MMSE score > 10; AND
  • GDS score between 4 to 6; AND
  • Improvement or stabilization in at least one of the following domains (please indicate improved, worsened, or no change)
  1. Memory, reasoning and perception (e.g., names, tasks,MMSE)
  2. Instrumental activities of daily living (IADLs: e.g., telephone, shopping, meal preparation)
  3. Basic activities of daily living (e.g., bathing, dressing, hygiene, toileting)
  4. Neuropsychiatric symptoms (e.g. agitation, delusion, hallucination, apathy)

Not Added To Formulary

The following drugs will not be added to the NIHB Drug Benefit List:
DIN MFR Item Name
02349124 LIL EFFIENT 10MG TABLET (PRASUGREL)
02344939 NOV ILARIS 150MG/VIAL INJECTION (CANAKINUMAB)
02354233 JNO INVEGA SUSTENA 100MG/1ML INJECTION (PALIPERIDONE PALMITATE)
02354241 JNO INVEGA SUSTENA 150MG/1.5ML INJECTION (PALIPERIDONE PALMITATE)
02354209 JNO INVEGA SUSTENA 25MG/0.25ML INJECTION (PALIPERIDONE PALMITATE)
02354217 JNO INVEGA SUSTENA 50MG/0.5ML INJECTION (PALIPERIDONE PALMITATE)
02354225 JNO INVEGA SUSTENA 75MG/0.75ML INJECTION (PALIPERIDONE PALMITATE)
02350580 BMR KUVAN 100MG TABLET (SAPROPTERIN DIHYDROCHLORIDE)

Criteria Changes

Listings of Lantus

Effective April 1, 2011, NIHB has listed Lantus® as an open benefit on the Drug Benefit List. This change in listing status will apply to the following DINs:

02245689 LANTUS® 100UNIT/ML 10ML VIAL
02251930 LANTUS® 100UNIT/ML CARTRIDGE
02294338 LANTUS® 3ML SOLOSTAR

Listings of Methadone for Pain

Effective, June 1, 2011, the listing status of methadone for the treatment of pain has been changed from exception to limited use benefit (prior approval required) with the following criteria:

  1. Prescriber is registered with Health Canada and is eligible to prescribe methadone for the management of pain. AND
  2. For the management of moderate to severe cancer pain or chronic non-cancer pain, as an alternative to other opioids. OR,
  3. For the management of pain for palliative care patients.

Metadol® 1mg Tablet 02247698
Metadol® 5mg Tablet 02247699
Metadol® 10mg Tablet 02247700
Metadol® 25mg Tablet 02247701
Metadol® 1mg/ml Liquid 02247694
Metadol® 10mg/ml Liquid 02241377
Methadone powder (pain) 09991180

Pharmacists may only dispense a maximum supply of 30 days at one time.

Methadone pseudo DINs listed for the treatment of pain should not be used for methadone maintenance therapy. Methadone for the treatment of opioid dependency is an open benefit covered under the NIHB Program (Methadone maintenance therapy pseudo DIN 908835). For information regarding the adjudication rules of methadone for the treatment of opioid dependency, please refer to the NIHB Provider Guide for Pharmacy Benefits.

Listings of Concerta

Effective April 1, 2011, NIHB has listed Concerta® as a limited use benefit, prior approval required.

This change in listing status will apply to the following DINs:

02247732 CONCERTA® 18MG Tablet
02250241 CONCERTA® 27MG Tablet
02247733 CONCERTA® 36MG Tablet
02247734 CONCERTA® 54MG Tablet

This change in listing status will also affect the following generic methylphenidate ER products:

02315068 NOVO-METHYLPHENIDATE ER 18MG Tablet
02315076 NOVO-METHYLPHENIDATE ER 27MG Tablet
02315084 NOVO-METHYLPHENIDATE ER 36MG Tablet
02315092 NOVO-METHYLPHENIDATE ER 54MG Tablet
02330377 APO-METHYLPHENIDATE ER 54MG Tablet

The limited use benefit (prior approval required) criteria for Concerta® (and generics) are:

For the treatment of patients aged 6 to 18 with Attention Deficit Hyperactivity Disorder (ADHD) who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interferes with learning AND for whom the medication is prescribed by, or in consultation with, a specialist in pediatric psychiatry, pediatrics, or a general practitioner with expertise in ADHD, AND for whom sustained release methylphenidate (i.e., Ritalin® SR) or sustained release dextroamphetamine (i.e., Dexedrine Spansules) has not adequately controlled the symptoms of the disorder.

Listings of Januvia and Janumet

Effective July 15, 2011, NIHB listed Januvia and Janumet as limited use benefits, prior approval required, with the following criteria.

Limited use benefit (prior approval required)

For treatment of type 2 diabetic patients who are not adequately controlled by or are intolerant to metformin and sulfonylureas or for whom these products are contraindicated.

This change in listing status applies to the following DINs.

02303922 JANUVIA® 100MG TAB
02333856 JANUMET® 50MG/500MG TAB
02333864 JANUMET® 50MG/850MG TAB
02333872 JANUMET® 50MG/1000MG TAB

Januvia and Janumet are eligible for Auto Approval through the NIHB Program.

New Oxycontin Dose Limit

The Non-Insured Health Benefits (NIHB) Program has developed a strategy to address the potential misuse and abuse of OxyContin®. This strategy was based on recommendations by the National Opioid Use Guidelines Group (NOUGG) and developed in consultation with the Drug Use Evaluations Advisory Committee (DUEAC). The mandate of the DUEAC is to provide recommendations to NIHB to promote safe, therapeutically effective and efficient use of drug therapy as it contributes to the health outcomes of First Nations and Inuit clients.

The first phase of the NIHB OxyContin® strategy was implemented on October 18, 2010 when the Program revised the coverage criteria for OxyContin®. OxyContin® is now eligible for a maximum supply of 30 days at one time and requires previous use of an alternative long acting opioid (e.g. morphine LA) before coverage is provided.

On February 15, 2011, NIHB placed a dose limit on OxyContin®, in Ontario only, of 36000 morphine mg equivalents over 60 days (equivalent to 600 morphine mg equivalents per day or 400mg of OxyContin® per day) when used to treat non-cancer or non- palliative pain.

Effective July 26, 2011, NIHB will change the dose limit to 60000 morphine mg equivalents over 100 days, and implement it on a national basis. This is equivalent to 600 morphine mg equivalents per day or 400mg of OxyContin® per day. The dose limit will apply for any combination of the following DINs when used to treat non-cancer or non-palliative pain.

  • OxyContin® 5 mg tab (DIN 02258129)
  • OxyContin®10 mg tab (DIN 02202441)
  • OxyContin® 15 mg tab (DIN 02323192)
  • OxyContin® 20 mg tab (DIN 02202468)
  • OxyContin® 30 mg tab (DIN 02323206)
  • OxyContin® 40 mg tab (DIN 02202476)
  • OxyContin® 60 mg tab (DIN 02323214)
  • OxyContin® 80 mg tab (DIN 02202484)

If a request for coverage is received from the pharmacy provider resulting in the client exceeding the eligible dose limit, the client's prescriber will need to provide rationale to the NIHB Drug Exception Centre (DEC) to support the additional doses. OxyContin® used to treat cancer or palliative care pain will not be subjected to this dose limit.

The NIHB Program will continue to monitor the utilization of OxyContin® and adjust the eligible dose limit as required.

The NIHB Program relies on continued support from pharmacists in our efforts to ensure the safer use of OxyContin® among First Nations and Inuit clients.

Delisting of OTC Cough and Cold Products

Effective July 4, 2011, the NIHB Program is no longer providing coverage of OTC cough and cold products due to a lack of proven efficacy and as well the potential risks of harm for children under 6. This change in listing status will apply to the following DINs currently listed on the NIHB DBL:

02243969 DIMETAPP DM COUGH & COLD
00896179 TRIAMINIC DM NIGHT TIME
02241495 DM COUGH SYRUP
02215268 BENYLIN DM CHILD
01928775 BALMINIL DM
01944738 BENYLIN DM
00511013 DM SANS SUCRE
01928791 KOFFEX DM RPH
02231404 BENYLIN DM NIGHTTIME
02018403 DELSYM
02231313 TRIAMINIC DM
01953966 ROBITUSSIN PEDIATRIC
00729655 BUCKLEYS DM BUY
00522791 BRONCHOPHAN FORTE DM
00800813 COUGH SYRUP RPH
00833231 COUGH SYRUP DEXTROMETHORPHAN
01928783 KOFFEX DM RPH
02243062 TRIAMINIC COUGH & CONGESTION
01944746 BENYLIN DM-D CHILD WLA
01944711 BENYLIN DM-D WLA
02238302 ACTIFED
02243980 DIMETAPP COLD
01970399 CHLOR-TRIPOLON ND SCH
01944746 BENYLIN DM-D CHILD WLA.

Date Modified: 2011-09-12

Top of Page
Important Notices